ArticleMolecular oncology2015
Oncolytic vaccinia virus synergizes with irinotecan in colorectal cancer.
Article in Molecular oncology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 34 citations in OpenAlex.
- Review
- TG6002 oncolytic vaccinia virus and chemotherapy synergy: a promising strategy for pancreatic ductal adenocarcinoma.Frontiers in microbiology · 2025Article
- Combination of FOLFOXIRI Drugs with Oncolytic Coxsackie B3 Virus PD-H Synergistically Induces Oncolysis in the Refractory Colorectal Cancer Cell Line Colo320.International journal of molecular sciences · 2024Article
- The Future of Interventions for Stage IV Colorectal Cancers.Clinics in colon and rectal surgery · 2024Review
- Recent progress in combination therapy of oncolytic vaccinia virus.Frontiers in immunology · 2024Review
- A new strategy for treating colorectal cancer: Regulating the influence of intestinal flora and oncolytic virus on interferon.Molecular therapy oncolytics · 2023Review
- Vaccinia virus and peptide-receptor radiotherapy synergize to improve treatment of peritoneal carcinomatosis.Molecular therapy oncolytics · 2023Article
- Oncolytic virotherapy: basic principles, recent advances and future directions.Signal transduction and targeted therapy · 2023Review
- Colorectal cancer and gut viruses: a visualized analysis based on CiteSpace knowledge graph.Frontiers in microbiology · 2023Article
- The employment of vaccinia virus for colorectal cancer treatment: A review of preclinical and clinical studies.Human vaccines & immunotherapeutics · 2022Review
- Cutting both ways: the innate immune response to oncolytic virotherapy.Cancer gene therapy · 2022Review
- Current clinical landscape of oncolytic viruses as novel cancer immunotherapeutic and recent preclinical advancements.Frontiers in immunology · 2022Review
- Deletion of immunomodulatory genes as a novel approach to oncolytic vaccinia virus development.Molecular therapy oncolytics · 2021Article
- Immuno-Oncolytic Viruses: Emerging Options in the Treatment of Colorectal Cancer.Molecular diagnosis & therapy · 2021Review
- Inhibition of colorectal cancer liver metastasis in BALB/c mice following intratumoral injection of oncolytic herpes simplex virus type 2 for the induction of specific antitumor immunity.Oncology letters · 2019Article
- Immunotherapeutic advances in gastrointestinal malignancies.NPJ precision oncology · 2019Review
- Gene module analysis of juvenile myelomonocytic leukemia and screening of anticancer drugs.Oncology reports · 2018Article
- A novel oral camptothecin analog, gimatecan, exhibits superior antitumor efficacy than irinotecan toward esophageal squamous cell carcinoma in vitro and in vivo.Cell death & disease · 2018Article
- Chemovirotherapy of Pancreatic Adenocarcinoma by Combining Oncolytic Vaccinia Virus GLV-1h68 withMolecular therapy oncolytics · 2017Article
- Dasatinib synergises with irinotecan to suppress hepatocellular carcinoma via inhibiting the protein synthesis of PLK1.British journal of cancer · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
Metastatic colorectal cancer (CRC) is complex clinical challenge for which there are limited treatment options. Chemotherapy with or without surgery provides moderate improvements in overall survival and quality of life; nevertheless the 5-year survival remains below 30%. Oncolytic vaccinia virus (VV) shows strong anti-tumour activity in models of CRC, however transient delays in disease progression are insufficient to lead to long-term survival. Here we examined the efficacy of VV with oxaliplatin or SN-38 (active metabolite of irinotecan) in CRC cell lines in vitro and VV with irinotecan in an orthotopic model of metastatic CRC. Synergistic improvements in in vitro cell killing were observed in multiple cell lines. Combination therapy was well tolerated in tumour-bearing mice and the median survival was significantly increased relative to monotherapy despite a drug-dependent decrease in the mean tumour titer. Increased apoptosis following in vitro and in vivo combination therapy was observed. In vitro cell cycle analysis showed increases in S-phase cells following infection occurred in both infected and uninfected cell populations. This corresponded to a 4-fold greater increase in apoptosis in the uninfected compared to infected cells following combination therapy. Combination treatment strategies are among the best options for patients with advanced cancers. VV is currently under clinical investigation in patients with CRC and the data presented here suggest that its combination with irinotecan may provide benefit to a subset of CRC patients. Further, investigation of this combination is necessary to determine the tumour characteristics responsible for mediating synergy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.